Clinical Trial Search

Primary: Percentage of Participants Obtaining Successful Treatment — 4; 3; 2 Participants

Primary: Change From Baseline in the Facial Angiofibroma Grading Scale (AGS) Score — -13.89; -12.71; -1.39 score on a scale

Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale

Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001

Primary: IGA of Improvement — 3.1; 3.5 units on a scale

Primary: The Change in Number of Facial Inflammatory Acne-related Lesions. — 46; 23.7 Lesions

Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 39; 6; 2 Participants

Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale

Primary: Objective Response Rate — 44.4 percentage of participants

Primary: 3D Photographic Measurement of Surface Volume of Cutaneous Neurofibroma Lesion — 32.54; 33.93 mm^3

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24 — -1.8; -0.5 score on a scale

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: MRI/MRA of Head/Neck/Chest. — 357 participants

Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale

Primary: Confirmed Response Rate (CR or PR) Using RECIST — 0 percentage of participants

Primary: Complete Response Rate — 2 Participants

Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 35; 36; 49 Participants

Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001

Primary: Median Progression-free Survival of Patients Treated With the Study Drug as Defined by RECIST Criteria. — 12.4 Weeks

Primary: Mean Changes in Color, Texture, and Size of Cherry Angiomata From Baseline to 3 Months After the Second Treatment by Treatment Type as Assessed by Blinded Raters — 5.27…

Primary: Subject Satisfaction — 2.8 score on a scale

Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage

Primary: Evaluator Live Acne Scarring Assessment Responders — 64; 46 Participants — p=0.0109

Primary: Total Number of Cleared SH Lesions — 99.5 Percentage of cleared SH Lesions

Primary: Changes in Facial Scarring Score — -.50 score on a scale

Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale

Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants

Primary: Phospho-erk (p-ERK) Levels of Target cNF Tumors in NFX-179 Gel Group and Vehicle Gel Group After 28 Days of Once-daily (QD) Application — 0.3054; 0.2734; 0.2267; 0.1627…